These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 17245540

  • 1. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK, ATAC Trialists' Group.
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A, Verma S.
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [Abstract] [Full Text] [Related]

  • 10. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM, Rubio-Terrés C, Del Castillo A, González P, Canorea F.
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer].
    Sasse AD, Sasse EC.
    Rev Assoc Med Bras (1992); 2009 May; 55(5):535-40. PubMed ID: 19918652
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 17. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C, Rayson D, Dewar R, Younis T.
    Breast; 2007 Jun 15; 16(3):252-61. PubMed ID: 17207623
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C, Keam SJ.
    Pharmacoeconomics; 2006 Jun 15; 24(5):495-517. PubMed ID: 16706574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.